Renaissance Technologies LLC Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Renaissance Technologies LLC trimmed its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 63.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 776,990 shares of the biotechnology company’s stock after selling 1,351,831 shares during the period. Renaissance Technologies LLC’s holdings in BioCryst Pharmaceuticals were worth $7,397,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the period. Goldman Sachs Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after buying an additional 640,704 shares in the last quarter. Caxton Associates LLP purchased a new stake in BioCryst Pharmaceuticals during the first quarter worth $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after buying an additional 47,355 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BCRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Cantor Fitzgerald raised their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Royal Bank Of Canada increased their price target on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $20.80.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $8.81 on Tuesday. The company has a fifty day moving average of $9.31 and a two-hundred day moving average of $8.66. The stock has a market capitalization of $2.24 billion, a PE ratio of -4.95 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same period in the prior year, the firm earned $0.20 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.